Key facts
- This page summarizes John M. Evans's Form 4 filing for Beam Therapeutics Inc. (BEAM).
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 16 Oct 2026, 20:09.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Options Exercise
Sale
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2026.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.23 to $23.84, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.66 to $24.56, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F4
On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.